BioCryst Pharmaceuticals | BCRX - Pre Tax Profit


BioCryst Pharmaceuticals reported $248.02M in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
Alnylam Pharmaceuticals USD 221.65M 60.52M Mar/2026
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
Chugai Pharma JPY 160.2B 9.71B Mar/2026
Daiichi Sankyo JPY 106.73B 48.96B Dec/2025
DBV Technologies USD -47.4M 14.24M Mar/2026
Enanta Pharmaceuticals USD -22.71M 95.08M Dec/2024
Gilead Sciences USD 2.08B 1.56B Dec/2025
GlaxoSmithKline GBP 2.14B 919M Mar/2026
Glaxosmithkline GBP 2.14B 312M Mar/2026
Incyte USD 343.6M 46.34M Mar/2026
Ionis Pharmaceuticals USD -93M 135M Mar/2026
Karyopharm Therapeutics USD -39.9M 9.01M Dec/2025
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Novavax USD 17.9M 220.94M Dec/2025
PTC Therapeutics USD -2.46M 136.62M Mar/2026
Regeneron Pharmaceuticals USD 1.04B 719.6M Dec/2025
Roche Holding CHF 4.79B 3.01B Jun/2025
Sarepta Therapeutics USD 343.17M 750.85M Mar/2026
Ultragenyx Pharmaceutical USD -184M 56M Mar/2026
Vertex Pharmaceuticals USD 1.25B 78.1M Mar/2026